NASDAQ:CALA Calithera Biosciences (CALA) Stock Forecast, Price & News $0.05 0.00 (0.00%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$0.05▼$0.0550-Day Range$0.02▼$0.0852-Week Range$0.01▼$3.68Volume781 shsAverage Volume134,546 shsMarket Capitalization$243,600.00P/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability About Calithera Biosciences (NASDAQ:CALA) StockCalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Read More CALA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CALA Stock News HeadlinesSeptember 27, 2023 | americanbankingnews.comCalithera Biosciences (NASDAQ:CALA) Now Covered by StockNews.comSeptember 19, 2023 | americanbankingnews.comCalithera Biosciences (NASDAQ:CALA) Receives New Coverage from Analysts at StockNews.comSeptember 28, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.August 12, 2023 | npr.orgChristina CalaJune 29, 2023 | seekingalpha.comCalithera Biosciences cancels special meeting due to lack of quorumJune 1, 2023 | finance.yahoo.comCALA - Calithera Biosciences, Inc.May 20, 2023 | finanznachrichten.deCalithera Biosciences, Inc.: Calithera Biosciences Announces Update on Complete Liquidation and DissolutionMay 19, 2023 | travel.usnews.comCala MarioluSeptember 28, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.May 19, 2023 | seekingalpha.comCalithera Biosciences plans special meeting to seek approval for liquidation and dissolution planMay 19, 2023 | finance.yahoo.comCalithera Biosciences Announces Update on Complete Liquidation and DissolutionMay 13, 2023 | travel.usnews.comCala LlombardsMay 12, 2023 | investing.comCalithera Biosciences Inc (CALA) Earnings Dates & ReportsJanuary 11, 2023 | marketwatch.comCalithera Biosciences Shares Plummet on Liquidation Plans >CALAJanuary 11, 2023 | marketwatch.comCalithera Biosciences to Liquidate >CALAJanuary 10, 2023 | finance.yahoo.comBiotech company Calithera plans its own death. Will others follow?January 9, 2023 | finanznachrichten.deCalithera Biosciences, Inc.: Calithera Biosciences Announces Board Approval of Complete Liquidation and DissolutionJanuary 9, 2023 | markets.businessinsider.comCalithera Biosciences Board Of Directors Determine Dissolution Of CompanyJanuary 9, 2023 | finance.yahoo.comCalithera Biosciences Stock Nosedives On Complete Liquidation, DissolutionJanuary 9, 2023 | finance.yahoo.comCalithera Biosciences Announces Board Approval of Complete Liquidation and DissolutionNovember 15, 2022 | finanznachrichten.deCalithera Biosciences, Inc.: Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business UpdateNovember 15, 2022 | seekingalpha.comCalithera Biosciences, Inc. (CALA) Q3 2022 Earnings Call TranscriptNovember 15, 2022 | finance.yahoo.comCalithera Biosciences Reports Third Quarter 2022 Financial Results and Business UpdateNovember 8, 2022 | finance.yahoo.comCalithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022October 3, 2022 | marketwatch.comCalithera Biosciences Gets FDA Fast Track For Lung Cancer DrugOctober 3, 2022 | nasdaq.comCalithera Gets FDA Fast Track Designation For Sapanisertib For Squamous Lung Cancer TreatmentOctober 3, 2022 | finance.yahoo.comCalithera's stock is up 14% after announcing Fast Track designation for lung-cancer drug candidateSee More Headlines Receive CALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CALA Company Calendar Last Earnings11/08/2021Today9/28/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CALA CUSIPN/A CIK1496671 Webwww.calithera.com Phone(650) 870-1000FaxN/AEmployees8Year Founded2010Profitability EPS (Most Recent Fiscal Year)($25.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,336.25% Return on Assets-98.17% Debt Debt-to-Equity RatioN/A Current Ratio3.60 Quick Ratio3.60 Sales & Book Value Annual Sales$9.75 million Price / Sales0.02 Cash FlowN/A Price / Cash FlowN/A Book Value($0.40) per share Price / Book-0.13Miscellaneous Outstanding Shares4,872,000Free Float4,550,000Market Cap$243,600.00 OptionableOptionable Beta0.28 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Susan M. Molineaux Ph.D. (Age 69)Founder, CEO, Pres & Director Comp: $625.81kMs. Stephanie Wong (Age 49)CFO & Sec. Comp: $752.42kDr. Christopher J. Molineaux Ph.D. (Age 70)Sr. VP of Devel. Mr. Frank Parlati Ph.D. (Age 54)Sr. VP of Research Dr. Susan B. Demo Ph.D.Sr. VP of R&D OperationsDr. Allison Dillon Ph.D.Sr. VP of Commercial & Portfolio StrategyMore ExecutivesKey CompetitorsLannettNYSE:LCINSciSparcNASDAQ:SPRCPLx PharmaNASDAQ:PLXPOncorusNASDAQ:ONCRNovanNASDAQ:NOVNQView All CompetitorsInsidersDeepika PakianathanSold 121,333 sharesTotal: $47,319.87 ($0.39/share)View All Insider Transactions CALA Stock - Frequently Asked Questions Should I buy or sell Calithera Biosciences stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CALA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CALA, but not buy additional shares or sell existing shares. View CALA analyst ratings or view top-rated stocks. How have CALA shares performed in 2023? Calithera Biosciences' stock was trading at $3.26 at the beginning of 2023. Since then, CALA shares have decreased by 98.5% and is now trading at $0.05. View the best growth stocks for 2023 here. When is Calithera Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our CALA earnings forecast. How were Calithera Biosciences' earnings last quarter? Calithera Biosciences, Inc. (NASDAQ:CALA) issued its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($3.00) EPS for the quarter, beating analysts' consensus estimates of ($4.60) by $1.60. The biotechnology company had revenue of $6.75 million for the quarter. During the same period last year, the firm earned ($6.40) EPS. When did Calithera Biosciences' stock split? Calithera Biosciences shares reverse split before market open on Wednesday, June 15th 2022. The 1-20 reverse split was announced on Wednesday, June 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Calithera Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX), Rigel Pharmaceuticals (RIGL), First Solar (FSLR), Plug Power (PLUG) and Sorrento Therapeutics (SRNE). What is Calithera Biosciences' stock symbol? Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA." How do I buy shares of Calithera Biosciences? Shares of CALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Calithera Biosciences' stock price today? One share of CALA stock can currently be purchased for approximately $0.05. How much money does Calithera Biosciences make? Calithera Biosciences (NASDAQ:CALA) has a market capitalization of $243,600.00 and generates $9.75 million in revenue each year. The biotechnology company earns $-39,650,000.00 in net income (profit) each year or ($25.60) on an earnings per share basis. How can I contact Calithera Biosciences? Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.calithera.com. The biotechnology company can be reached via phone at (650) 870-1000 or via email at ir@calithera.com. This page (NASDAQ:CALA) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calithera Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.